In the fast-paced realm of drug discovery, Molecule GEN stands as a beacon of innovation, promising a quantum leap in the way we approach pharmaceutical br...
CDS software serves as the primary interface for lab analysts, making user interface and user experience important considerations when being developed. Add...
In today’s evolving industrial landscape, the concept of Industry 4.0 is revolutionizing various sectors by leveraging digitalization and automation ...
This post continues the discussion of optimization opportunities for GC labs, focusing on headspace sampling for the efficient and automated analysis of vo...
Choosing the right HPLC detector for your workflow falls in the second category. Preparing to update, implement or adopt a new HPLC method requires to unde...
A hallmark of many neurodegenerative disorders is the accumulation of damaged or abnormally folded proteins. The impact of such intracellular accumulations...
One notable technique is the utility of liquid biopsies to provide real-time insights into tumor evolution and treatment response. Liquid biopsies are part...
Using radioactive ligand binding methods, Dr. Snyder’s team found that the receptors were highly concentrated in areas of the brain involved in the s...
With an effective process validation regimen – with proper documentation and protocol testing to address product identity, strength, quality, purity,...
LC/MS/MS instruments use two quadrupole mass analyzers in series, with a collision cell in between, to provide higher sensitivity and selectivity for targe...
But developing a bispecific antibody presents several challenges, including those related to dual binding, screening, pharmacodynamics, tissue tropism, and...
Unlocking early biological changes Fluorescence imaging offers researchers a unique opportunity to understand the early biological changes associated with...
These figures were disappointing for many, especially since TB is a treatable disease. The standard treatment typically requires six months of antibiotics...
“Every tumor is different, and the one-size-fits-all approach doesn’t work for patients,” said Dr. Nikolaus Krall, Vice President Preci...
© 2025 Biopharma Boardroom. All Rights Reserved.
